The aim of this study was to observe the rate of thromboembolic and hemorrhagic events in a period of 2 years in 167 patients undergoing appendage occlusion with Amplatzer device. Appendage occlusion in patients with contraindication to anticoagulation is a safe technique associated with less embolic and bleeding events than expected according to the risk…
Bivalirudin superior than heparin beyond the use or not of Glycoprotein inhibitors
Bivalirudin benefits in bleeding events versus heparin plus glycoprotein IIbIIIa inhibitors is clear even though this benefit has not been fully studied at the point whether persists when glycoprotein inhibitors are used only for rescue and not routinely. This is an EUROMAX sub-analysis that included 2198 patients experiencing AMI analyzing events at 30 days. Bivalirudin…
TRIPLETE RESET trial: comparison of platelet reactivity with clopidogrel, prasugrel or ticagrelor.
The individual variability to platelet response of clopidogrel is related to several mechanisms with high intrinsic platelet reactivity, variability in drug metabolism, drug interactions, etc. The hepatic cytochrome P450 system plays a key role in the metabolism of clopidogrel, and the CYP2C19 allele loss of function is associated with high platelet reactivity with clopidogrel use…
COMPARE II: biolimus eluting stent with biodegradable polymer versus everolimus at 3 years.
This study randomized 2:1 – 2707 patients to biolimus eluting stent with biodegradable polymer versus everolimus eluting stent with permanent polymer. At one year, the results were similar demonstrating the biolimus eluting stent noninferiority. At three years cardiac death, myocardial infarction and target vessel revascularization rates remained similar with 11% for biolimus eluting stent and…
PARIS register: Non-adherence impact to antiplatelet therapy among men and women
The PARIS registry was a prospective observational study in 5018 patients undergoing coronary angioplasty with stent implantation in 15 centers. Three categories were prespecified in the discontinuation of dual antiplatelet therapy: 1) discontinuation for medical guidance, 2) transient discontinuation for less than 15 days for surgery and 3) permanent abandonment of it by non-adherence or…
Meta-analysis confirms the reduction in ischemic events with 2nd generation DES versus BMS
This paper included 5 studies that randomized patients to conventional stent versus chromium cobalt everolimus eluting stent; at 2 years, a significantly lower risk of cardiac death (2.7% for the everolimus eluting stent versus 4% for conventional stent, p = 0013) was observed. Myocardial infarction was reduced by over 80% with drug-eluting stent (0.08% versus…
Safety and efficacy of Cardiobrand device for percutaneous mitral annuloplasty
The Cadiobrand device is implanted through a transseptal approach and makes a reduction in the mitral annulus area. The study included 24 patients with moderate mitral regurgitation (functional class III- IV) and high surgical risk. The device was successfully implanted in all cases reducing the annular size by 92 % and to the same extent…
SALUS: New percutaneous valve with promising results regarding aortic regurgitation post implant.
Aortic regurgitation after valve implantation has been shown to be a long -term mortality predictor. The aim of this study was to test the new Direct Flow Medical system, which is more flexible prosthesis with a lower profile that could result in minor aortic regurgitation and less need for post expansion. This multicenter study included…
DESSOLVE II: 2-year results show the superiority of the sirolimus eluting stent with fast bio -absorbable polymer.
The aim of this study was to evaluate the performance of the sirolimus eluting stent with bio -absorbable polymer (MiStent SES) compared with zotarolimus eluting stent with permanent polymer (Endeavor). This 2:1 randomized, multicenter study included 183 patients with the primary objective of evaluating the late lumen loss between the MiStent and Endeavor a two…
ACCOAST: pretreatment with prasugrel in non-ST elevation acute coronary syndrome (NSTE-ACS) offers no benefit and increased bleeding
P2Y12 receptor inhibitors are effective in patients experiencing NSTE-ACS, however, the administration timing is not clear. This study evaluated the administration of prasugrel at the time of diagnosis of ACS or after performing coronary angiography when angioplasty was already decided. 4033 patients were included experiencing an NSTE-ACS troponin positive who had planned angiography between 2…
SORT-OUT V: Similar results of biolimus eluting stent with biodegradable polymer versus sirolimus eluting stent with permanent polymer.
The last results of the SORT OUT V submitted in PCR 2012 showed that biolimus eluting stent with biodegradable polymer was not able to reach the non-inferiority versus sirolimus eluting stent with permanent polymer. Results to 3 years are now available, and the new device reached the non-inferiority with a MACE rate of 11.2% for…
- 1
- 2